Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab add-on to TNF inhibitor in ulcerative colitis
NCT03123120Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2017
- Primary completion
- Mar 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing Spesolimab with Placebo (2 arms). Primary endpoint: Proportion of Participants With Endoscopic Improvement (MCS mESS ≤1) at 12 weeks. Started Jun 2017; status: completed.
02
Drugs
spesolimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03123120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123120.